Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
The company said Zepbound, or tirzepatide, is the first and only prescription medicine for adults suffering from this condition. The drug was launched in the U.S. for the treatment of adults with obesity or who are overweight with weight-related comorbidities in November 2023.
This story is from the December 23, 2024 edition of The Wall Street Journal.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 23, 2024 edition of The Wall Street Journal.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In